Related Experiment Video
Updated: May 26, 2026

A Rat Dry Eye Model with Lacrimal Gland Dysfunction Induced by Scopolamine
Published on: February 9, 2024
The scopolamine model of dementia: chronic transdermal administration
C Brazell1, G C Preston, C Ward
1Neuroscience Research Centre, Merck, Sharp and Dohme, Terlings Park, Eastwick Road, Harlow, Essex, UK.
Abstract:
The transient impairments of memory produced by the muscarinic antagonist scopolamine have been adopted as a pharmacological model of Alzheimer-type dementia in normal volunteers. In this study we examined the effects of chronic (72 h) transdermal administration of scopolamine on memory, attention, sedation and visual function. The transdermal patches provided constant plasma levels of scopolamine for the duration of the study. Indices of the peripheral effects of scopolamine (visual near-point and pupil size) showed impairments that were sustained for 3 days. However, measures of sedation and memory revealed impairments that were maximal the day after patch application and which were no longer present 3 days after application. This pattern of results is discussed in relation to pharmacological modelling of Alzheimer's disease.
More Related Videos
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
08:28Using Pharmacological Manipulation and High-precision Radio Telemetry to Study the Spatial Cognition in Free-ranging Animals
Published on: November 6, 2016
Related Concept Videos
Dementia l: Introduction
Transdermal Drug Delivery Systems
Alzheimer's Disease: Treatment
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...